Insulet (NASDAQ:PODD) Shares Gap Up – Here’s Why

Shares of Insulet Corporation (NASDAQ:PODD) gapped up prior to trading on Tuesday . The stock had previously closed at $138.97, but opened at $143.00. Insulet shares last traded at $144.3340, with a volume of 122,179 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. The Goldman Sachs Group reiterated a “buy” rating and set a $205.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Piper Sandler lowered their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. UBS Group set a $219.00 target price on shares of Insulet in a research report on Thursday, June 11th. Raymond James Financial set a $216.00 price target on shares of Insulet in a report on Monday, June 8th. Finally, Wells Fargo & Company reduced their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Twenty-two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $238.67.

Insulet Trading Up 3.6%

The business has a 50 day simple moving average of $162.97 and a 200 day simple moving average of $224.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company has a market cap of $9.97 billion, a price-to-earnings ratio of 33.51, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same period last year, the company posted $1.02 earnings per share. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts forecast that Insulet Corporation will post 6.46 EPS for the current year.

Insiders Place Their Bets

In related news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.36% of the company’s stock.

Institutional Trading of Insulet

A number of hedge funds and other institutional investors have recently modified their holdings of PODD. Glenmede Investment Management LP boosted its position in Insulet by 1.6% in the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC raised its position in shares of Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares during the last quarter. WINTON GROUP Ltd lifted its stake in shares of Insulet by 0.9% during the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after acquiring an additional 37 shares during the period. Great Lakes Advisors LLC lifted its stake in shares of Insulet by 1.5% during the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after acquiring an additional 40 shares during the period. Finally, Camarda Financial Advisors LLC boosted its holdings in Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.